The number-one challenge facing the biopharmaceutical industry today is public distrust, dwarfing concerns about regulatory obstacles or the sheer difficulty of the science required to develop drugs, a survey of STAT Plus subscribers shows.
Much of the public’s poor opinion of biopharma stems from runaway drug price hikes, and survey respondents had a lot to say about strategies being pursued in Washington to corral these costs. They give high marks to the tax law and brush off any concern about import tariffs.
This is an annoying story. When reporting on survey results it’s pretty common to actually show the results, in the form of graphs and tables for each question. In this story, we are at the mercy of qualitative interpretation.
Comments are closed.